Market Overview

JPMorgan Downgrades Mersana, Says Data Readouts Unlikely To Reverse Street Sentiment

JPMorgan Downgrades Mersana, Says Data Readouts Unlikely To Reverse Street Sentiment

Mersana Therapeutics Inc (NASDAQ: MRSN) shares, which went public in March 2018, was hit with its first bearish rating Monday in the absence of any stock-impacting data readouts over the next 12 months.

The Analyst

JPMorgan analyst Jessica Fye downgraded Mersana from Neutral to Underweight and withdrew the previous $10 price target.

The Thesis

With $160 million pro forma cash and an enterprise value of $55 million, Mersana shares already reflect substantial market skepticism, Fye said in the Monday downgrade note. 

Upcoming data releases are unlikely to reverse the prevailing sentiment, the analyst said. 

Fye said she sees sufficient runway for Mersana to generate expansion cohort data for its lead asset XMT-1536, with the initial dose escalation readout in January signaling activity.

" ... Confirmation of durable benefit is what we think will be needed to drive the market to ascribe more value to this asset." 

Updated dose escalation data due in the second quarter — with a mix of doses, tumor types and NaPi2b expression levels — is unlikely to answer the question, let alone provide a strong read on the potential for success in future studies, the analyst said. 

The Price Action

Mersana shares were down 0.66 percent at $4.49 at the time of publication Monday. 

Related Links:

The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs

Analysts Positive On Insys Ahead Of 2019 Pipeline Catalysts

Latest Ratings for MRSN

May 2020BairdMaintainsOutperform
May 2020SVB LeerinkReiteratesOutperform
May 2020H.C. WainwrightReiteratesBuy

View More Analyst Ratings for MRSN
View the Latest Analyst Ratings


Related Articles (MRSN)

View Comments and Join the Discussion!

Posted-In: Jessica Fye JPMorganAnalyst Color Biotech Downgrades Analyst Ratings General Best of Benzinga

Latest Ratings

ASHEvercore ISI GroupInitiates Coverage On80.0
RPMEvercore ISI GroupInitiates Coverage On90.0
DOWEvercore ISI GroupInitiates Coverage On58.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at